May 29, 2019Open Access

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Key Points

Key points are not available for this paper at this time.

Abstract

In this study, combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL. (Funded by AbbVie and others; ClinicalTrials.gov number, NCT02756897.).

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Key Points

Abstract

Cite This Study